Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion

被引：0
|
作者：
Abduelmula, Abrahim [1 ]
Gooderham, Melinda J. [2 ,3 ,4 ,5 ]
机构：
[1] Univ Western Ontario, Fac Med, London, ON, Canada
[2] Queens Univ, Kingston, ON, Canada
[3] SKiN Ctr Dermatol, Peterborough, ON, Canada
[4] Prob Med Res, Peterborough, ON, Canada
[5] SKiN Ctr Dermatol, 775 Monaghan Rd S, Peterborough, ON K9J 5K2, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2023年 / 27卷 / 03期
关键词：
psoriasis; halobetasol propionate and tazarotene; treatment; systemic therapy; real-world experience; topical;
D O I：
10.1177/12034754231163541
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：293 / 294
页数：2
相关论文
共 50 条
  • [1] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Brownstone, Nicholas D.
    Bhutani, Tina
    Koo, John
    [J]. CURRENT DERMATOLOGY REPORTS, 2021, 10 (01) : 21 - 25
  • [2] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Nicholas D. Brownstone
    Tina Bhutani
    John Koo
    [J]. Current Dermatology Reports, 2021, 10 : 21 - 25
  • [3] Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
    Reddy, Vidhatha
    Myers, Bridget
    Yang, Eric J.
    Bhutani, Tina
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2020, 13 : 391 - 398
  • [4] Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion
    Gold, L. F. Stein
    Lebwohl, M. G.
    Bhatia, N.
    Lin, T.
    Pillai, R.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S82 - S82
  • [5] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
    Kircik, Leon H.
    Papp, Kim A.
    Gold, Linda Stein
    Harris, Susan
    Lin, Tina
    Pillai, Radhakrishnan
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
  • [6] Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion
    Desai, Seemal R.
    Alexis, Andrew F.
    Jacobson, Abby
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 1000 - 1004
  • [7] A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis
    Radonjic, Aleksandar
    Evans, Emily L.
    [J]. DERMATOLOGIC THERAPY, 2019, 32 (04)
  • [8] Efficacy, Safety, and Tolerability of Halobetasol Propionate 0.01%-Tazarotene 0.045% Lotion for Moderate to Severe Plaque Psoriasis in the Hispanic Population: Post Hoc Analysis
    Alexis, Andrew F.
    Yamauchi, Paul S.
    Desai, Seemal R.
    Khaselev, Nelly
    Lin, Tina
    [J]. CUTIS, 2020, 105 (03): : 150 - +
  • [9] Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis
    Lebwohl, Mark G.
    Del Rosso, James Q.
    Alonso-Llamazares, Javier
    Lattouf, Mark
    Jacobson, Abby
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB130 - AB130
  • [10] Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
    Lebwohl, Mark G.
    Gold, Linda Stein
    Del Rosso, James Q.
    Green, Lawrence
    Jacobson, Abby
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2068 - 2074
12345